ClinicalTrials.gg
RecruitingNCT06079671eVOLVECervicalUpdated Nov 10, 2026

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

A Phase 3 interventional study of Volrustomig and Placebo in Locally Advanced Cervical Cancer, sponsored by AstraZeneca. Recruiting at 205 sites in 19 countries. Open to female participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Updated Nov 10, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
15 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Uterine Cervical Neoplasms by AstraZeneca — 3 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · AstraZeneca.

Started
2023
the only one that year
Phase 3
2 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Uterine Cervical Neoplasms by AstraZeneca, this one is the only one that started in 2023, is one of 2 in phase 3, and was the 7th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 11 studies in Uterine Cervical Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 15 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Uterine Cervical Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Read the detailed description

Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.

03

Conditions studied

  • Locally Advanced Cervical Cancer

Keywords

  • Locally Advanced Cervical Cancer;
  • Adolescent and Young Adult;
  • Volrustomig
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  1. Female.
  2. Aged at least 15 years at the time of screening. Note: Participants \< 18 years of age: physical changes should be aligned with Tanner Stage III.
  3. Body weight > 35 kg.
  4. documented FIGO 2018 Stage IIIA to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with no evidence of disease.
  5. Initial staging procedures performed no more than 56 days prior to the first dose of CCRT.
  6. Provision of FFPE tumor sample to assess the expression.
  7. Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent.
  8. performance status of 0 or 1; duration of of ≥ 12 weeks.
  9. Adequate organ and bone marrow function.
  10. Capable of providing signed .

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Diagnosis of small cell (neuroendocrine) or mucinous adenocarcinoma of cervical cancer.
  2. Evidence of disease.
  3. Intent to administer a fertility-sparing treatment regimen.
  4. History of organ transplant or allogenic stem cell transplant.
  5. History of active primary immunodeficiency or active or prior documented or inflammatory disorders.
  6. Uncontrolled intercurrent illness.
  7. History of another primary except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease.
  8. Unresolved toxicities from previous CCRT except for irreversible toxicity that is not reasonably expected to be exacerbated.
  9. Prior history or presence of vesicovaginal, colovaginal, or rectovaginal fistula.
  10. History of anaphylaxis to any biologic therapy or vaccine.
  11. Current or prior use of medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical , or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control); c) Physiologic doses of oral corticosteroids, ie, not exceeding 10 mg/day of prednisone (or equivalent) in the preceding 14 days.
  12. Patients who have undergone a previous hysterectomy, including a supracervical hysterectomy, or will have a hysterectomy as part of their initial cervical cancer therapy.
  13. Any prior (besides prior CCRT) or concurrent treatment for cervical cancer.
  14. Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery.
  15. Exposure to immune mediated therapy prior to the study for any indication.
  16. Receipt of within 30 days prior to the first dose of the study intervention.
  17. Participants with a known allergy or hypersensitivity to the study intervention, or any of the study intervention.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Volrustomig

    Volrustomig

    Biological: Volrustomig

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalVolrustomig

    IV Infusion

  • OtherPlacebo

    IV Infusion

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)

    PFS is defined as the time from date of randomization until RECIST 1.1- defined radiological progression or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier.

    Time frame: Up to approximately 7 years

Secondary outcomes

  1. Overall Survival (OS) in all randomized participants

    OS defined as time from randomization until the date of death due to any cause.

    Time frame: Up to approximately 7 years

  2. Objective Response Rate (ORR) in all randomized participants

    ORR is defined as the proportion of participants who have a CR or PR, as determined by Investigator per RECIST 1.1

    Time frame: Up to approximately 7 years

  3. Duration of Response (DoR) in all randomized participants

    DoR in participants with a CR or PR: Time from date of first detection of CR or PR until the date of RECIST 1.1-defined radiological progression or histopathologically confirmed progression.

    Time frame: Up to approximately 7 years

  4. Time to First Subsequent Therapy or death (TFST) in all randomized participants

    TFST: The time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.

    Time frame: Up to approximately 7 years

  5. Time to second progression or death (PFS2) in all randomized participants

    PFS2: The time from randomization to the earliest of the progression event (following the initial Investigator-assessed progression), after first subsequent therapy, or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice.

    Time frame: Up to approximately 7 years

  6. PFS by BICR in all randomized participants

    Endpoints based on the PFS by BICR assessment according to RECIST 1.1.

    Time frame: Up to approximately 7 years

  7. The incidence of local progression, and distant disease progression as the first documented progression event in all randomized participants

    Incidence of Local Progression, and Distant Disease Progression: Number and percentage of participants who develop local progression, distant disease recurrence.

    Time frame: Up to approximately 7 years

  8. PK of volrustomig

    Concentration of volrustomig in serum and PK parameters as data allow.

    Time frame: Up to approximately 7 years

  9. The immunogenicity of volrustomig

    Incidence of ADAs against volrustomig in serum.

    Time frame: Up to approximately 7 years

  10. Incidence of adverse events of volrustomig compared to placebo

    An AE is defined as the development of any untoward medical occurrence (other than progression of the malignancy under evaluation) in a patient or clinical study participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 7 years

  11. Participant-reported disease-related symptoms

    Change from baseline as measured by the European Organization for Research and Treatment of Cancer IL318 (EORTC IL318, Symptom Experience subscale of the EORTC Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24)). The score of scale for EORTC IL318 is from 1-4.

    Time frame: Up to approximately 7 years

  12. Participant-reported physical functioning

    Change from baseline of physical functioning as measured by the Patient Reported Outcomes Measurement Information System - Short Form - Physical Functioning 8c (PROMIS SF-PF 8c). The score of scale for PROMIS SF-PF 8c is from 1-5.

    Time frame: Up to approximately 7 years

  13. Participant-reported global health status/Quality of Life

    Change from baseline of Global Health Status/ Quality of Life (GHS/QoL) as measured by the European Organization for Research and Treatment of Cancer IL172 (EORTC IL172). The score of scale for EORTC IL172 is from 1-7.

    Time frame: Up to approximately 7 years

07

Study locations

145 of 205 sites recruiting
  • Research Site
    Birmingham, Alabama 35233, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Phoenix, Arizona 85016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tucson, Arizona 85711, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Little Rock, Arkansas 72205, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    La Jolla, California 92093, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    West Hollywood, California 90048, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30322, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Augusta, Georgia 30912, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Savannah, Georgia 31405, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Melrose Park, Illinois 60160, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Indianapolis, Indiana 46202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New Orleans, Louisiana 70112, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New Orleans, Louisiana 70121, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shreveport, Louisiana 71103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Syracuse, New York 13210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Cleveland, Ohio 44195, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Columbus, Ohio 43210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Eugene, Oregon 97401, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Philadelphia, Pennsylvania 19107, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Providence, Rhode Island 02905, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Dallas, Texas 75390, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Worth, Texas 76104, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Houston, Texas 77030, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tyler, Texas 75702, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Charlottesville, Virginia 22908, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Fairfax, Virginia 22031, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Richmond, Virginia 23298, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Barretos, 14784-400, Brazil
    Recruiting
  • Research Site
    Belo Horizonte, 30130-100, Brazil
    Recruiting
  • Research Site
    Curitiba, 80730-150, Brazil
    Recruiting
  • Research Site
    Fortaleza, 60336-045, Brazil
    Recruiting
  • Research Site
    Fortaleza, 60430-230, Brazil
    Recruiting
  • Research Site
    Goiânia, 74110-060, Brazil
    Not yet recruiting
  • Research Site
    Ijuí, 98700-000, Brazil
    Recruiting
  • Research Site
    Natal, 59075-740, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90570-060, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90619-900, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 98850-170, Brazil
    Recruiting
  • Research Site
    Porto Velho, 76834-899, Brazil
    Recruiting
  • Research Site
    Recife, 52010-075, Brazil
    Recruiting
  • Research Site
    Rio de Janeiro, 20220-410, Brazil
    Recruiting
  • Research Site
    Salvador, 40050 410, Brazil
    Recruiting
  • Research Site
    São Paulo, 01246-000, Brazil
    Recruiting
  • Research Site
    São Paulo, 01323-000, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 1323001, Brazil
    Recruiting
  • Research Site
    Teresina, 64049-200, Brazil
    Recruiting
  • Research Site
    Hamilton, Ontario L8V 1C3, Canada
    Recruiting
  • Research Site
    London, Ontario N6A 5W9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
    Recruiting
  • Research Site
    Ste-Foy, Quebec G1V 4G2, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100026, China
    Recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Changde, 415000, China
    Recruiting
  • Research Site
    Changsha, 410008, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chengdu, 610044, China
    Recruiting
  • Research Site
    Chongqing, 400030, China
    Recruiting
  • Research Site
    Fuzhou, 350014, China
    Recruiting
  • Research Site
    Ganzhou, 341000, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Guangzhou, 510120, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hangzhou, 310022, China
    Recruiting
  • Research Site
    Harbin, 150081, China
    Recruiting
  • Research Site
    Kunming, 650118, China
    Recruiting
  • Research Site
    Lanzhou, 730000, China
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Lanzhou, 730050, China
    Recruiting
  • Research Site
    Linyi, 276001, China
    Recruiting
  • Research Site
    Luzhou, 646000, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nanchang, 330006, China
    Recruiting
  • Research Site
    Nanchang, 330029, China
    Recruiting
  • Research Site
    Shandong, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shanghai, 200032, China
    Recruiting
  • Research Site
    Shanghai, 200080, China
    Recruiting
  • Research Site
    Shenyang, 110004, China
    Recruiting
  • Research Site
    Shenzhen, 518036, China
    Recruiting
  • Research Site
    Shenzhen, 518116, China
    Recruiting
  • Research Site
    Tianjin, 300060, China
    Recruiting
  • Research Site
    Wuhan, 430022, China
    Recruiting
  • Research Site
    Wuhan, 430030, China
    Recruiting
  • Research Site
    Xi'an, 710061, China
    Recruiting
  • Research Site
    Yibin, 610500, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Yinchuan, 750004, China
    Recruiting
  • Research Site
    Zhengzhou, 450008, China
    Recruiting
  • Research Site
    Zhengzhou, 450052, China
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Zhuzhou, 412007, China
    Recruiting
  • Research Site
    Aarhus N, 8200, Denmark
    Recruiting
  • Research Site
    København Ø, 2100, Denmark
    Recruiting
  • Research Site
    Odense, 5000, Denmark
    Recruiting
  • Research Site
    Berlin, 13353, Germany
    Recruiting
  • Research Site
    Bonn, 53127, Germany
    Recruiting
  • Research Site
    Hamburg, 20246, Germany
    Recruiting
  • Research Site
    Leipzig, 04103, Germany
    Recruiting
  • Research Site
    Calicut, 673601, India
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Jaipur, 302017, India
    Recruiting

Showing the first 100 of 205 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2027, 50 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 50 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Oct 12, 2023
StartActual
Sep 22, 2023
Primary completionEst.
Nov 26, 2027
CompletionEst.
Sep 30, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (2 now recruiting, 2 now withdrawn)
Show 4 sites
  • Research Site · Porto Alegre, BrazilNot yet recruiting→Recruiting
  • Research Site · Ankara, Turkey (Türkiye)Recruiting→Withdrawn
  • Research Site · Ijuí, BrazilNot yet recruiting→Recruiting
  • Research Site · Wroclaw, PolandRecruiting→Withdrawn
across 2 updates, Sep 30, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites changed recruiting status (1 now recruiting, 1 now withdrawn)
    Show 2 sites
    • Research Site · Ijuí, BrazilNot yet recruiting→Recruiting
    • Research Site · Wroclaw, PolandRecruiting→Withdrawn
    + 1 other change: verification date
  2. Sep 30, 2026
    2 sites changed recruiting status (1 now recruiting, 1 now withdrawn)
    Show 2 sites
    • Research Site · Porto Alegre, BrazilNot yet recruiting→Recruiting
    • Research Site · Ankara, Turkey (Türkiye)Recruiting→Withdrawn
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06079671
Lead sponsor
AstraZeneca
Collaborators
Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Sep 22, 2023
Primary completion
Nov 26, 2027 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion